{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:41:53Z","timestamp":1759970513242,"version":"build-2065373602"},"reference-count":39,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Taiwan and Mongolia joint project","award":["TWN-2-2022\/03","112-2923-B-037-002-MY3"],"award-info":[{"award-number":["TWN-2-2022\/03","112-2923-B-037-002-MY3"]}]},{"name":"the National Science and Technology Council of Taiwan","award":["TWN-2-2022\/03","112-2923-B-037-002-MY3"],"award-info":[{"award-number":["TWN-2-2022\/03","112-2923-B-037-002-MY3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background: Hepatitis C virus (HCV) infection accelerates the progression of chronic kidney disease (CKD), increasing the risk of kidney failure and end-stage renal disease. Direct-acting antiviral (DAA) therapies for HCV infection inhibit viral replication by 95\u201397%, leading to a sustained virologic response. Our objective was to assess renal function in patients with chronic HCV infection in Taiwan after receiving DAA therapy. Goal: Our study included 4823 patients with HCV infection who were undergoing DAA therapy. Renal function was evaluated by calculating the glomerular filtration rate (eGFR). eGFR assessed at the initiation of the treatment, during treatment, and at 3 months, 6 months, 1 year, and 3 years after completion of treatment. The baseline demographic and laboratory parameters of the study participants were evaluated, and the results were analyzed using statistical methods. Results: The average age of the study participants was 61.35 \u00b1 12.50 years, and 54.5% of were male. The mean of eGFR in baseline and after treatment showed a decrease. Liver fibrosis scores (FIB4, APRI, Fibroscan) and liver function tests were significantly improved after DAA treatment (p = 0.001). However, white blood count (5.41 \u00b1 1.7 vs. 5.73 \u00b1 1.9), platelet count (168.04 \u00b1 74.0 vs. 182.11 \u00b1 69.4), and creatinine levels (1.05 \u00b1 1.3 vs. 1.12 \u00b1 1.3) increased after treatment (p = 0.001). The number of patients with an eGFR of 60 mL\/min\/1.73 m2 decreased both during and after treatment (p &lt; 0.001). Among patients with CKD, eGFR improved after DAA treatment (n = 690, 35.93 \u00b1 19.7 vs. 38.71 \u00b1 23.8; 95% CI \u22123.56\u20131.98; p = 0.001). Logistic regression analysis revealed that renal function improved in patients with CKD who had an eGFR of less than 60 mL\/min\/1.73 m2 before DAA treatment (OR 1.62, 95% CI 1.37\u20131.91, p = 0.001). Conclusions: In individuals with CKD and a baseline eGFR &lt; 60 mL\/min per 1.73 m2, eGFR level was increased during DAA treatment. This suggests that initiating DAA therapy in HCV-infected patients, even those without clinical manifestations, could be a crucial strategy to prevent further decline in renal function.<\/jats:p>","DOI":"10.3390\/diseases13020026","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T08:46:26Z","timestamp":1737449186000},"page":"26","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Change in Estimated Glomerular Filtration Rate After Direct-Acting Antiviral Treatment in Chronic Hepatitis C Patients"],"prefix":"10.3390","volume":"13","author":[{"given":"Gantogtokh","family":"Dashjamts","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar 14210, Mongolia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin-Erdene","family":"Ganzorig","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar 14210, Mongolia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1512-4055","authenticated-orcid":false,"given":"Yumchinsuren","family":"Tsedendorj","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar 14210, Mongolia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-951X","authenticated-orcid":false,"given":"Dolgion","family":"Daramjav","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar 14210, Mongolia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enkhmend","family":"Khayankhyarvaa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar 14210, Mongolia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bolor","family":"Ulziitsogt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar 14210, Mongolia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otgongerel","family":"Nergui","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar 14210, Mongolia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-6996","authenticated-orcid":false,"given":"Ganchimeg","family":"Dondov","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar 14210, Mongolia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9982-949X","authenticated-orcid":false,"given":"Tegshjargal","family":"Badamjav","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar 14210, Mongolia"},{"name":"Department of Biological Sciences, School of Life Sciences, Inner Mongolia University, Hohhot 010031, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulgaa","family":"Lonjid","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar 14210, Mongolia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Feng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807378, Taiwan"},{"name":"Department of Occupational and Environmental Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807378, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Cheng","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807378, Taiwan"},{"name":"Department of Occupational and Environmental Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807378, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3109-2166","authenticated-orcid":false,"given":"Batbold","family":"Batsaikhan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar 14210, Mongolia"},{"name":"Department of Health Research, Graduate School, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2296-3054","authenticated-orcid":false,"given":"Chia-Yen","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807378, Taiwan"},{"name":"Ph.D. Program in Environmental and Occupational Medicine, Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung 807378, Taiwan"},{"name":"College of Professional Studies, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3350\/cmh.2022.0349","article-title":"Acute hepatitis C virus infection: Clinical update and remaining challenges","volume":"29","author":"Liu","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_4","first-page":"2051","article-title":"Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: Optimizing use of peginterferon alfa","volume":"9","author":"Liu","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mazzaro, C., Quartuccio, L., Adinolfi, L.E., Roccatello, D., Pozzato, G., Nevola, R., Tonizzo, M., Gitto, S., Andreone, P., and Gattei, V. (2021). A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. Viruses, 13.","DOI":"10.3390\/v13112249"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/jvh.12199","article-title":"Age and gender differences in the relationship between hepatitis C infection and all stages of Chronic kidney disease","volume":"21","author":"Li","year":"2014","journal-title":"J. Viral Hepat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/j.ajkd.2012.04.003","article-title":"Association of hepatitis C virus infection with risk of ESRD: A population-based study","volume":"60","author":"Su","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lee, J.J., Lin, M.Y., Chang, J.S., Hung, C.C., Chang, J.M., Chen, H.C., Yu, M.L., and Hwang, S.J. (2014). Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100790"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.27664","article-title":"Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans","volume":"61","author":"Molnar","year":"2015","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jhep.2017.12.003","article-title":"Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis","volume":"68","author":"Soderholm","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","article-title":"A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): A phase 4, open-label, single-arm trial","volume":"7","author":"Solomon","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/jvh.13484","article-title":"Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass","volume":"28","author":"Tokuchi","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1111\/jgh.14275","article-title":"Association between cryoglobulinemia and liver fibrosis in chronic hepatitis C patients","volume":"33","author":"Batsaikhan","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Batsaikhan, B., Huang, C.I., Yeh, M.L., Huang, C.F., Lin, Y.H., Liang, P.C., Hsieh, M.Y., Lin, Y.C., Huang, J.F., and Chuang, W.L. (2022). Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0268180"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Dashjamts, G., Ganzorig, A.E., Tsedendorj, Y., Dondov, G., Nergui, O., Badamjav, T., Huang, C.F., Liang, P.C., Lonjid, T., and Batsaikhan, B. (2024). Post-Treatment Occurrence of Serum Cryoglobulinemia in Chronic Hepatitis C Patients. Diagnostics, 14.","DOI":"10.3390\/diagnostics14111188"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7326\/0003-4819-144-10-200605160-00007","article-title":"Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation","volume":"144","author":"McGuire","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12072-011-9284-9","article-title":"Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection","volume":"6","author":"Satapathy","year":"2012","journal-title":"Hepatol. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e1334","DOI":"10.1097\/MD.0000000000001334","article-title":"A Taiwanese Nationwide Cohort Study Shows Interferon-Based Therapy for Chronic Hepatitis C Reduces the Risk of Chronic Kidney Disease","volume":"94","author":"Chen","year":"2015","journal-title":"Medicine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"Hsu","year":"2015","journal-title":"Gut"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/lt.23756","article-title":"Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease","volume":"20","author":"Ble","year":"2014","journal-title":"Liver Transpl."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2215\/CJN.02510317","article-title":"Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD","volume":"12","author":"Sise","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40261-017-0526-z","article-title":"Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens","volume":"37","author":"Puenpatom","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jama.2009.1488","article-title":"Cardiovascular and noncardiovascular mortality among patients starting dialysis","volume":"302","author":"Grootendorst","year":"2009","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.26892","article-title":"Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2015.09.007","article-title":"Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies","volume":"150","author":"Petta","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_29","first-page":"32","article-title":"An update on the management of hepatitis C virus-infected patients with stage 4-5 chronic kidney disease while awaiting the revised KDIGO Guidelines","volume":"32","author":"Pol","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/jgh3.12324","article-title":"Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals","volume":"4","author":"Nevola","year":"2020","journal-title":"JGH Open"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/JCMA.0000000000000561","article-title":"The association between hepatitis C virus infection and renal function","volume":"84","author":"Gantumur","year":"2021","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1435124","DOI":"10.1080\/19932820.2018.1435124","article-title":"Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs","volume":"13","author":"Soliman","year":"2018","journal-title":"Libyan J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/00365521.2018.1473486","article-title":"Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication\u2014Comparison of the new direct-acting antiviral agents with the old regimens","volume":"53","author":"Carvalho","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"E203","DOI":"10.1111\/hepr.12970","article-title":"Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with hepatitis C virus","volume":"48","author":"Inoue","year":"2018","journal-title":"Hepatol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Hashimoto, S., Yatsuhashi, H., Abiru, S., Yamasaki, K., Komori, A., Nagaoka, S., Saeki, A., Uchida, S., Bekki, S., and Kugiyama, Y. (2016). Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163644"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/sdi.12097","article-title":"Hepatitis C virus screening and management of seroconversions in hemodialysis facilities","volume":"26","author":"Mbaeyi","year":"2013","journal-title":"Semin. Dial."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41581-018-0081-8","article-title":"Hepatitis C virus and the kidney","volume":"15","author":"Pol","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents","volume":"63","author":"Sise","year":"2016","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40620-019-00608-z","article-title":"Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection","volume":"32","author":"Coppola","year":"2019","journal-title":"J. Nephrol."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/2\/26\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:33:02Z","timestamp":1759919582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/2\/26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["diseases13020026"],"URL":"https:\/\/doi.org\/10.3390\/diseases13020026","relation":{},"ISSN":["2079-9721"],"issn-type":[{"type":"electronic","value":"2079-9721"}],"subject":[],"published":{"date-parts":[[2025,1,21]]}}}